Pharmaceutical opioid deaths in presence of witnesses
A new study supports the trialing of education and/or naloxone to partners and family members in order to reduce overdose deaths.
Rowan Ogeil, Jeremy Dwyer, Lyndal Bugeja, Cherie Heilbronn, Dan Lubman and Belinda Lloyd.
Download the complete article (purchase or subscription required)
In the past two decades, rates of pharmaceutical opioid use and harms resulting from their use (including death) have risen. The present study identified a series of fatal opioid overdoses where there was evidence that witnesses had noted symptoms consistent with overdose, and examined associated contextual factors
A retrospective review was undertaken utilising the Coroners Court of Victoria’s Overdose Deaths Register for pharmaceutical opioid overdose deaths between 2011 and 2013. Information on the source of pharmaceutical opioids, co-contributing drugs, history of drug dependence, and mental illness was extracted and coded.
Pharmaceutical opioids were involved in 587 deaths, and within these, 125 cases (21%) were witnessed. The majority of these witnessed deaths (77.6%) occurred at the deceased’s residence, with the witness being a partner or unrelated acquaintance who did not realise the significance of what they were witnessing. The most common contributing pharmaceutical opioids were methadone (49.6%), codeine (32.0%), and oxycodone (19.2%), with the source more often prescribed than diverted. Co-contributing drugs were involved in 110 cases, with the most common being benzodiazepines. Evidence of current dependence and mental illness was found in 53.6% of cases.
Most pharmaceutical opioid overdose deaths with a witness present occurred in the deceased’s home, with symptoms of overdose being noted, but not acted upon. These findings support the trialling of education and/or naloxone to reduce overdose deaths.